Matthew Posard Sells 18,996 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew Posard sold 18,996 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Price Performance

NASDAQ HALO traded up $1.24 during trading hours on Thursday, reaching $109.68. The company’s stock had a trading volume of 1,983,627 shares, compared to its average volume of 1,833,846. The stock has a market cap of $12.45 billion, a PE ratio of 32.74, a PEG ratio of 0.40 and a beta of 0.88. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $111.15. The company’s 50-day moving average is $95.33 and its two-hundred day moving average is $77.80. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on HALO. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the company from $83.00 to $110.00 in a report on Friday, August 7th. Finally, Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Twin Capital Management Inc. boosted its holdings in shares of Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 161 shares during the last quarter. Pzena Investment Management LLC boosted its holdings in shares of Halozyme Therapeutics by 4.2% in the 4th quarter. Pzena Investment Management LLC now owns 4,278 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 171 shares during the last quarter. First Citizens Bank & Trust Co. grew its stake in shares of Halozyme Therapeutics by 2.0% during the 1st quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 175 shares during the period. Finally, Nations Financial Group Inc. IA ADV increased its holdings in shares of Halozyme Therapeutics by 1.2% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock worth $981,000 after buying an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.